Fig 1: CALCR promotes malignant phenotypes of renal carcinoma cells. (A) Cell proliferative capacities of 786-O and ACHN cells transfected with shCtrl or shCALCR lentivirus were evaluated by Celigo cell count assay. (B) Alterations of cell apoptosis in 786-O and ACHN cells transfected with shCtrl or shCALCR lentivirus were analyzed by flow cytometry. (C, D) Cell migratory abilities of 786-O and ACHN cells transfected with shCtrl or shCALCR lentivirus were assessed by (C) transwell assay and (D) wound-healing assay. (E) The effect of CALCR on cell cycle distribution was analyzed by flow cytometry. The representative images were selected from at least 3 independent experiments. Results were presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.
Fig 2: Overexpression of CALCR predicts poor prognosis for patients with renal carcinoma. (A) Representative IHC images of CALCR expression in human RCC tissues and normal para-carcinoma tissues. Scale bar represent 50 μm. (B) Quantification of CALCR expression in IHC staining. (C) Kaplan-Meier analysis indicated that high CALCR expression was correlated with short PFS. Results were presented as mean ± SD. **p < 0.01, ***p < 0.001. Abbreviations: CALCR: calcitonin receptor; IHC: immunohistochemical; PFS: progression-free survival.
Fig 3: CALCR mediated renal carcinoma progression is depended on CD44. CALCR overexpression and CD44 depletion in 786-O cell were confirmed by (A) qPCR and (B) western blot assays. GAPDH served as an internal control in qPCR and western blot assays. (C) Cell viability in 786-O cell transfected with indicated lentiviruses was assessed by Celigo cell count assay. (D) Cellular apoptosis in 786-O cell transfected with indicated lentiviruses was evaluated using flow cytometry. (E) Cell migration was analyzed by wound-healing assays. The representative images were selected from at least 3 independent experiments. Results were presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.
Fig 4: Possible signaling pathways that contribute to renal carcinoma progression. (A) IPA analysis identified the interaction between CALCR and NF-κB signaling, integrin signaling, PI3K/AKT signaling, ERK/MAPK signaling, Wnt/β-catenin signaling and NGF signaling. (B) Human phospho-kinase array analysis suggested the significant changes in phosphorylation levels of c-jun and STAT1 after silencing CALCR. Results were presented as mean ± SD. *p < 0.05, **p < 0.01. Abbreviations: IPA: ingenuity pathway analysis; NF-κB: nuclear factor-kappa B; PI3K: phosphoinositide 3-kinase; AKT: protein kinase B; ERK: extracellular signal-regulated kinase; MAPK: mitogen-activated protein kinase; Wnt: wingless-related integration site; NGF: nerve growth factor; STAT1: signal transducer and activator of transcription 1.
Fig 5: CALCR stabilizes CD44 via inhibiting its ubiquitination. (A) Relative mRNA levels of several potential target genes were detected by qPCR analysis in ACHN cell with CALCR depletion. (B) Venn diagram showing the DEGs correlated with CALCR expression and shorted OS in TCGA renal clear cell carcinoma. (C) Relative mRNA expression of CD44 from TCGA renal cancer (KICH, KIRC and KIRP). (D) Relative protein levels of CALCR and CD44 in 786-O cells with CALCR deficiency were determined by western blot assays. (E) Co-IP analysis suggested the endogenous binding between CALCR and CD44. (F) Relative CD44 protein level in CALCR-depleted 786-O and ACHN cells treated with CHX was analyzed by western blot assays. (G) Relative CD44 protein level in CALCR-depleted 786-O and ACHN cells treated with MG132 was determined by western blot assays. (H) The ubiquitin of CD44 immunoprecipitated by anti-CD44 or IgG antibody was detected. GAPDH served as an internal control in qPCR and western blot assays. Results were presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations: DEGs: differentially expressed genes; OS: overall survival; TCGA: the Cancer Genome Atlas; CD44: cluster of differentiation; KICH: kidney chromophobe; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; CHX: Cycloheximide.
Supplier Page from Abcam for Anti-Calcitonin receptor/CT-R antibody